crestonepharma.com
Open in
urlscan Pro
2606:4700:20::681a:6b4
Public Scan
Submitted URL: http://www.crestonepharma.com/
Effective URL: https://crestonepharma.com/
Submission: On November 15 via api from US — Scanned from DE
Effective URL: https://crestonepharma.com/
Submission: On November 15 via api from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
info@crestonepharma.com * Follow * Follow * Follow * Company * About Us * Team * Code of Ethics * Careers * Press Releases * Pipeline * CRS3123 for C. difficile * CRS0540 Gram-positives * CRS0393 NTM/TB * Knowledge Portal * Contact Us * 19-0021 Clinical Study * Company * About Us * Team * Code of Ethics * Careers * Press Releases * Pipeline * CRS3123 for C. difficile * CRS0540 Gram-positives * CRS0393 NTM/TB * Knowledge Portal * Contact Us * 19-0021 Clinical Study Breaking the Cycle of Bacterial Growth and Resistance AN INNOVATIVE BIOTECH COMPANY IN BOULDER, CO. Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company developing new drug candidates with entirely novel mechanisms. Our research pipeline includes: C. diff treatment, antibiotic-resistant Gram-positive infection treatments, Tuberculosis treatments, and more. Read More See our progress PIPELINE MORE Enroll today CLINICAL STUDIES MORE Get the latest news PRESS RELEASES MORE Get to know us OUR TEAM MORE WHO WE ARE Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action small molecule drugs for serious bacterial infections. Our pipeline includes antibacterial agents aiming to treat a variety of serious conditions caused by antibacterial-resistant microbes, from C. difficile infection to MRSA, tuberculosis, and more. MORE ABOUT CRESTONE OUR PIPELINE Our R&D pipeline includes several programs that address areas of significant and growing unmet medical need, such as C. diff infection, all with novel mechanism of action agents. LEARN MORE CLINICAL STUDIES CLINICAL STUDY 19-0021 | C. DIFF INFECTION TREATMENT A Randomized, Double-blind Evaluation of CRS3123 Versus Oral Vancomycin in Adult Patients with Clostridioides difficile Infection. Phase II is enrolling now—find a clinical site near you and contact the study coordinator to see if you may be eligible to participate! Learn More About This Study & Enrollment KNOWLEDGE PORTAL WHAT IS YOUR RISK OF DEVELOPING A C. DIFFICILE INFECTION? Clostridioides difficile is a bacterium that is found in the intestines of humans and animals and in the environment. Certain strains of this organism can produce toxins that cause damage... BROWSE MORE INFORMATION & NEWS BECOME A PART OF OUR PROJECTS Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies. INQUIRIES Have a question or comment? Follow the link below to contact us about general inquiries. Contact Us CAREERS Find work in a team-oriented environment at one of the leading Colorado pharma companies. Join Crestone CLINICAL STUDIES Learn how you can become part of our ongoing clinical study to fight deadly GI tract infections. Enroll Today Copyright © Crestone Inc. 2022. All Rights Reserved. Website by tekRESCUE Enrollment is Now Open for the 19-0021 Clinical Study Learn More ×